Biography

Marcin Straburzyński, MD, PhD, is an associate professor of family medicine at the University of Warmia and Mazury’s Department of Family Medicine and Infectious Diseases in Olsztyn. His clinical roles combine general practice with an extended role as a consultant in headache and facial pain.

Dr. Straburzyński serves as Secretary for both the Polish Headache Society and the Headache Section of the Polish Neurological Society. He also presided over the Warmia & Mazury Division of the College of Family Physicians (2021–2026) and chaired the organizing committee for the annual Headache in Everyday Practice symposium series (2017–2022).

His scientific contributions include co-directing the landmark "Migraine in Poland" nationwide survey and researching the neurological etiologies of "sinus headache"—work that resulted in an international proposal to revise the diagnostic criteria for this condition. Additionally, he has co-authored Polish guidelines for headache management, written several national book chapters, and published numerous articles in international scientific journals.

Disclosures

Employment: University of Warmia and Mazury’s Department of Family Medicine and Infectious Diseases in Olsztyn

Leadership/Board position: Secretary of the Polish Headache Society; Secretary of the Headache Section of the Polish Neurological Society

Professional membership: College of Family Physicians in Poland; Polish Neurologic Society; Polish Headache Society; Polish Society of Family Medicine; Polish Rhinologic Society

Personal fees: Amgen; Neuca S.A.; Pfizer Polska; Teva Pharmaceuticals Polska; Synoptis Pharma

Clinical trails involvement: PI at: A Phase 3, Randomized, double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Erenumab in Children (6 to < 12 Years) and Adolescents (12 to < 18 Years) With Episodic Migraine (OASIS PEDIATRIC [EM]); A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Erenumab in Children (6 to < 12 Years) and Adolescents (12 to < 18 Years) With Chronic Migraine (OASIS PEDIATRIC [CM]); A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention in Children and Adolescents ≥ 6 to <18 years of age

Relationship with scientific journals:

Reviewer for: The Journal of Headache and Pain; Headache; Cephalalgia; Health Science Reports; Therapeutic advances in neurological disorders; PloS one; Pain management; Journal of pain research; Journal of clinical medicine; Expert review of neurotherapeutics; Dental and Medical Problems